Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Net Income: 2019-2025

Historic Net Income for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$305.2 million.

  • Revolution Medicines' Net Income fell 95.28% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$960.9 million, marking a year-over-year decrease of 69.46%. This contributed to the annual value of -$600.0 million for FY2024, which is 37.51% down from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Net Income is -$305.2 million, which was down 23.17% from -$247.8 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Net Income registered a high of -$37.2 million during Q1 2021, and its lowest value of -$305.2 million during Q3 2025.
  • Moreover, its 3-year median value for Net Income was -$156.3 million (2024), whereas its average is -$163.9 million.
  • Data for Revolution Medicines' Net Income shows a maximum YoY crashed of 185.87% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Revolution Medicines' Net Income stood at -$52.7 million in 2021, then declined by 7.27% to -$56.5 million in 2022, then tumbled by 185.87% to -$161.5 million in 2023, then declined by 20.42% to -$194.5 million in 2024, then slumped by 95.28% to -$305.2 million in 2025.
  • Its Net Income was -$305.2 million in Q3 2025, compared to -$247.8 million in Q2 2025 and -$213.4 million in Q1 2025.